	US 12,264,333 B2
	Colostrum derived stem cells, neural differentiation, compositions and supplements for enhancing mammalian health
Dilruba Hilal Gul-Uludag, Edmonton (CA); and Robert Edward Burrell, Sherwood Park (CA)
Assigned to MyStem Biotechnologies Inc., Edmonton (CA)
Appl. No. 17/274,404
Filed by MyStem Biotechnologies Inc., Edmonton (CA)
PCT Filed Sep. 20, 2019, PCT No. PCT/CA2019/051343 § 371(c)(1), (2) Date Mar. 8, 2021, PCT Pub. No. WO2020/056521, PCT Pub. Date Mar. 26, 2020.
Claims priority of provisional application 62/734,127, filed on Sep. 20, 2018.
Prior Publication US 2021/0269769 A1, Sep. 2, 2021
Int. Cl. C12N 5/074 (2010.01); A61K 35/28 (2015.01); A61K 35/30 (2015.01); C12N 5/079 (2010.01); C12N 5/0793 (2010.01)

CPC C12N 5/0607 (2013.01) [A61K 35/28 (2013.01); A61K 35/30 (2013.01); C12N 5/0619 (2013.01); C12N 5/0622 (2013.01); C12N 2501/998 (2013.01); C12N 2506/03 (2013.01)]

17 Claims

1. A method of producing a population of stem cells capable of providing an antimicrobial effect, comprising:

a) obtaining a population of colostrum derived stem cells; and

b) culturing the colostrum derived stem cells to provide adherent stem cells; and including one or both of:

i) obtaining the population of colostrum derived stem cells from a female mammal in an inflammatory state; and

ii) culturing the colostrum derived stem cells with an inflammatory inducing agent;

to provide a population of adherent colostrum derived stem cells capable of providing an antimicrobial effect.